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A median number of 4 segments was used (2-12) within a tangential 
two field irradiation technique. 357 (70,69%) of breasts needed ≥4 
segments to obtain a homogeneous dose. To report the acute toxicity 
(6 months follow up included), the RTOG/EORTC scale was used, while 
for late toxicity the SOMA LENT scale was used. 
Results: The median follow-up of this group of patients was 11 mts(1-
37 mts). One patient was dead at the last follow up, with distant 
metastases and 7 presented progressive disease: 5 distant, 1 local and 
1 infrapectoral. 




End of RT 
(505 pts) 
At 6 mts 
(420 pts) 
At 12 mts 
(232 pts) 
At ≥24 mts 
(54 pts) 
G0 119 327 203 52 
G1 327 92 28 2 
G2 55 1 1 1 
G3 4 0 0 0 
 
Twenty-one of 505 pts(4,16%) presented a delayed acute toxicity, 5-30 
days after the end of radiotherapy. 
Toxicity was intended as skin discoloration, oedema and fibrosis. No 
lung or heart toxicity were recorded. 
Conclusions: The hypofractionated FIMRT regimen (2,67 Gy/fr) used 
for WBRT in our institution allowed us to obtain a good acute and late 
toxicity, better than historical standard fractionation results, with no 
treatment interruptions.  
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Purpose/Objective: The FAST-Forward trial is a multicentre phase III 
trial comparing a 1-week course of curative breast radiotherapy (RT) 
against a standard 3-week schedule (ISRCTN19906132). The purpose of 
this study was to assess the applicability of field-based (FB) and 
volume based (VB) PTV for dosimetric data analysis and to evaluate 
the consistency of the results reported using them. 
Materials and Methods: The ongoing QA programme for the FAST-
Forward trial involves retrospective individual case reviews to be 
carried out and for the completion of a number of dose objectives 
reported for the treated breast volume and organs at risk. Depending 
upon the centre’s preference, both field-based (FB) and volume-based 
(VB) PTVs were accepted as plan evaluation structures. 
As very few centres routinely contour breast CTV and PTV, centres 
were instructed in the trial protocol to generate a field-based PTV, 
defined 5 mm from the skin, 5 mm from the lung / chest wall 
interface, 5 mm from the posterior beam and 10 mm from the 
superior and inferior beam edges. 
The trial protocol stipulated that the dose distribution across the 
selected dose reporting volume should be within the ICRU guidelines 
of –5% to +7%, with a coverage limit of V95% ≥ 95% and high dose limits 
of V105% ≤ 5% and V107% ≤ 2%. 
Each retrospective individual case review was assessed on this basis. 
Results: To date 338 plans have been collected from 9 RT centres. 
Eight of these used a FB planning approach and only one contoured a 
CTV and PTV. 
Based on plan reviews and centre feedback the following differences 
between the two structures can be summarised: 
- The FB approach resulted in a 5% to 50% larger reporting volume 
which often included non-breast tissue, especially in the superior end 
of the volume. Planners reported difficulties achieving 95% coverage 
in the superior end. 
- The VB approach produced a structure that was anatomically 
relevant but extended further towards the sternum and often the 
medial part of the VB PTV had to be excluded from the fields. 
Initial analysis of 15 plans from the centre using VB planning indicated 
that: 
- The reported target coverage was worse for the FB PTV than for the 
VB PTV, which means that some plans were rejected as suboptimal 
based on a FB PTV that would otherwise have been accepted. 
- VB plans would sometimes have 105% hotspots outside the VB PTV, 
which would not be reflected in the DVH. The reported V105% was 
equally likely to be increased or decreased when moving to a FB PTV. 
- It was noted that the centre using the VB technique exhibited on 
average a higher lung V30% dose and had a greater number of 
percentage deviations for the lung objective. 
Conclusions: The analysis of the data collected so far shows that both 
FB and VB PTVs can be used as breast plan evaluation structures 
providing the discrepancies we have discovered are considered.  
Further planned work includes extending the sample of VB plans and 
adding data from more centres using the VB approach. A CTV will be 
contoured for an additional sample of FB plans in order to further 
analyse the effect of the planning approach on the amount of lung 
included in the treatment fields. 
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Purpose/Objective: Several prognostic scores had been proposed in 
the literature to predict patient survival for brain metastasis from 
breast cancer. However, which score is most appropriate for these 
patients are still unknown. The aim of the study was to compare the 
four prognostic indexes predicting survival: the Recursive Partition 
Analysis (RPA), the Basic Score for Brain Metastasis (BSBM), the 
Breast-Cancer-Specific GPA (BC-GPA) and the breast cancer RPA (BC-
RPA) (Table 1).  
Materials and Methods: Eighty-seven patients (median age 48) with 
brain metastasis from breast cancer were evaluated. All patients 
treated with WBRT with or without surgery, radiosurgery and systemic 
therapy between January 2000 and December 2011. Survival time was 
measured from the time of first treatment of BM to the date of death 
or last follow-up. Survival curves were calculated by using Kaplan-Meir 
method. To identify clinical factors associated with survival time, Cox 
proportional hazard model was used.  
 
 Results: Median survival time (MST) for all patients was 8 months. MST 
of patients in the RPA classes I, II, III were 12, 8.3 and 3.4 months, 
respectively (p=0.001). MST of patients in the BC-RPA class I was 
undetectably longer than that of the patients in BC-RPA class II (8 
months) and class III (3.4 months) (p=<0.0001). According to the BSBM 
scoring system, MST of patients with score 0,1,2 and 3 were 2, 5.5, 
8.3 and 26.5 months (p=0.051), respectively. According to the BC-GPA 
scoring system, MST of patients with scores ranging 0.5-1, 1.5-2, 2.5-3 
and 3.5-4 were 3.4, 5.5, 8 and 20 months (p=0.001), respectively. 
Although the pairwise comparison of adjacent groups was found 
significant for RPA index[subclass I vs. II (p=0.041), subclass II vs. III 
(p=0.016)] and BC-RPAindex [subclass I vs. II (p=0.004), subclass II vs. 
III (p=0.003)], there were no survival differences between some pairs 
of groups for BSBM index [subgroup 0 vs. 1 (p=0.435), subgroup 1 vs. 2 
(p=0.178), subgroup 2 vs. 3 (p=0.042)] and BC-GPA index [subgroup 
0.5-1 vs. 1.5-2 (p=0.947), subgroup 1.5-2 vs. 2.5-3 (p=0.144), subgroup 
2.5-3 vs. 3.5-4 (p=0.144)] indexes. Regarding the prognostic factors in 
our population, only the BC-RPA prognostic index was found 
independent predictor on survival (HR=5.11, p=0.01) within other 
indexes. 
Conclusions: In the present study, we compared four proposed 
prognostic indexes which of two, the BC-GPA and BC-RPA, were new. 
We validated the utility of RPA and BC-RPA prognostic indexesfor 
breast cancer patients with brain metastasis. A new index, BC-RPA 
was found more prognostic compared to other indexes. Further 
assessing of the BC-RPA in future trials and direct comparison of the 
indexes in studies with large number of patients answer the question, 
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which index has the most prognostic power and which index is most 
useful for our daily practice? 
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Purpose/Objective: Several studies have shown that radiotherapy 
(RT) for breast cancer may be associated with an increased risk of 
heart disease. Most studies are based on patients treated before the 
era of CT-based radiotherapy, where 3D dose distributions are not 
available and dose to the heart volume needs to be estimated using 
other methods. In some previous studies a CT-scan of a representative 
patient was used to estimate heart dose, Taylor et al. (Int J Radiat 
Oncol Biol Phys2007;69:1484-95), Taylor et al. (Radiother Oncol 2009; 
90:127-35) and Taylor et al. (Radiother Oncol 2011;100:176-8). One 
limitation of this method was that inter-patient variation in heart 
dose for each technique was difficult to determine. The aim of this 
study was to estimate the variation in heart dose due to anatomical 
variation and patient movement from pre CT-based RT.  
Materials and Methods: 20 left- and 5 right-sided breast cancer 
patients treated with CT-based RT excluding the parasternal nodes 
following breast conserving surgery were selected at random from all 
women treated at our centre in 2010. The 2010 RT plan was used 
together with a reconstruction of the RT plan the patient would have 
received, if treated before the era of CT-based RT. This 
reconstruction was done according to historical guidelines using only 
external markers for field borders and machine output calculations. 
The 3D dose distributions were calculated in Pinnacle. The heart was 
contoured using a automatic method (ABAS by Elekta) with an atlas 
consisting of 15 patients. By a combination of blurring and random 
shifts of the dose, heart movement and setup uncertainty was 
simulated using a 5mm standard deviation for both the random and 
systematic error. 
Results: Mean and maximum doses to the heart are summarised in 
table 1 for the pre-CT and the 2010 CT-based RT by the median value 
and inter-quartile range (IQR). Figure 1 shows the distribution for the 
left-sided patients of mean and maximum heart doses. 
 
 
Conclusions: Non CT-planned RT does not allow precise patient-
specific sparing of organs at risk. This resulted in greater variation in 
mean heart doses in the pre CT era. The CT-planned RT included dose 
constraints to the heart and both the mean dose and the variation in 
mean dose were therefore lower. In general mean heart doses were 
low for both pre CT and CT-based RT, but the maximum doses for the 
left-sided patients showed that part of the heart received a high dose. 
The left anterior descending (LAD) coronary artery is typically located 
in this high dose region, and an increased risk of stenosis in the LAD 
following left-sided RT has indeed been reported. The approach 
applied in this study provides a method to estimate doses received by 
patients treated in the pre-CT era. Further work is needed to 
determine the doses and variations for other techniques commonly 
used in breast cancer RT, for example tangential RT including the 
parasternal lymph nodes, which is expected to result in higher heart 
doses.  
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Purpose/Objective: In the treatment of early breast cancer, axillary 
node clearance (ANC) or regional nodal irradiation following a positive 
sentinel lymph node (SLN) biopsy are therapeutic options providing 
equivalent local control. The ACOSOG Z0011 trial demonstrated 
equivalent overall survival and 5 year locoregional recurrence rates in 
patients with 1 or 2 positive SLNs offered either ANC or no further 
axillary treatment. It has been proposed that the incidental 
irradiation of lower axillary nodal levels by the whole breast 
tangential fields (TF) may explain these results. Our purpose was to 
evaluate the volume of axillary nodes encompassed within standard 
breast tangential fields, and analyse the dose delivered to each level.  
Materials and Methods: Levels 1, 2 and 3 axillary nodes were outlined 
retrospectively, using RTOG Breast Cancer Atlas Guidelines, on the 
axial CT simulation images of 50 patients who received whole breast 
irradiation alone following breast conserving surgery. Patients were 
immobilised on a breast board with both arms above their heads, and 
scanned using the local protocol. All patients received a standard dose 
and fractionation schedule with a biologically equivalent dose of 50Gy 
in 25 fractions. They were treated within ICRU 50 recommendations. 
The superior TF border was not manipulated to cover more of the 
axilla. Dose–volume histograms were used to calculate the percentage 
volume of each nodal level receiving 95% of the dose (V95%) and the 
mean dose [D mean(Gy)] at each level. 
 
 
Results: The mean dose delivered to each axillary node level was 
substantially lower than the prescribed dose. There was also a wide 
variation in the volume of levels 1 and 2 receiving 95% of the 
prescribed dose. V95% for level 3 was 0% for all patients, with a mean 
dose of only 1.8Gy. 
Conclusions: Levels 1 and 2 axillary nodes were only partially 
included in the tangential field set up. The dose delivered to all 
axillary nodal levels was lower than that considered therapeutic. 
There was a wide variation in the axillary dose coverage between 
patients. This was most likely related to multiple factors including 
patient shape and size, arm position and field borders. Certainly, our 
findings suggest that the use of standard breast radiotherapy field 
borders does not treat the axilla to a therapeutic dose and therefore 
cannot adequately explain the results seen in Z0011.  
Oncologists treating patients in the Z0011 trial may have used ‘high 
tangents’ in patients randomised to no further axillary intervention 
but these details have not yet been published. ‘High tangents’ involve 
altering the superior border of the tangential fields with the intention 
of including the lower nodal levels. Even with the use of ‘high 
tangents’, a therapeutic dose to the axilla may not be achieved. Until 
more information is available on the radiotherapy delivered within the 
Z0011 trial, we cannot assume its impact upon the results.  
 
